Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:09 PM
Ignite Modification Date:
2025-12-24 @ 5:09 PM
NCT ID:
NCT01535950
Eligibility Criteria:
Inclusion Criteria:
* Best corrected visual acuity (ETDRS scale) of 60 letters or less in the study eye.
* An active choroidal neovascular membrane attributable to neovascular AMD in at least one eye.
* History of treatment (at any time) with at least 3 doses of anti-VEGF therapy in the study eye.
Exclusion Criteria:
* History of recurrent non-response to anti-VEGF therapy in the study eye.
* In the study eye, retinal disease other than AMD (benign conditions of the vitreous and peripheral retina are not exclusionary).
* Choroidal neovascularization due to a cause other than AMD.
* In the study eye, media opacity that, in the investigator's opinion, could interfere with conduct of the study.
* History of infectious uveitis or endophthalmitis in either eye.
* Any of the following treatments to the study eye within 28 days prior to dosing: ranibizumab, bevacizumab, pegaptanib or other VEGF inhibitor.
* Any of the following within 90 days prior to dosing: photodynamic therapy or laser photocoagulation in the study eye; intravitreal steroid in the study eye; or intraocular surgery (including cataract surgery) in the study eye
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
55 Years
Maximum Age:
90 Years
Study:
NCT01535950
Study Brief:
Protocol Section:
NCT01535950